LYell SYndrome MEsenchymal Stromal Cells Treatment

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

LYell SYndrome MEsenchymal Stromal Cells Treatment

Official Title

Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial

Brief Summary

      Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous
      adverse reactions (SCARs) to drugs.

      To date, no curative drug has demonstrated with a good level of evidence its ability to
      promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal
      stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with
      cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute
      respiratory distress syndrome.

      Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of
      the unhealed burn area and in cutaneous radiation.

      Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and
      chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs.
      Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory
      cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their
      ability to promote tissue remodelling, angiogenesis and immunomodulation through either
      differentiation or secretion of several growth factors such as VEGF, basic FGF and various

      Therefore, combining their immunomodulation effect and secretion of soluble factors involved
      in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous
      healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Safety : Observation of at least one adverse effect

Secondary Outcome

 Rate of observed and predicted death by the SCORTEN


Epidermal Necrolysis


Adipose derived stromal cells intravenously injected

Study Arms / Comparison Groups

 Adipose derived stromal cells intravenously injected


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2022

Completion Date

September 2025

Primary Completion Date

September 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Patients aged from 18 to 75 years-old

          -  Admission less than 10 days after onset of the reaction

          -  Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology
             or intensive care medicine

          -  At least 10 % of detachable-detached body surface area at any time during the first 10
             days after the index date (date of the first symptoms of the disease)

          -  Written consent from patient or trustworthy person or legal representant or family

          -  Affiliated to a social security scheme

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  History of malignant disease within the past ten years and or presence of metastasis

          -  Positive serology for HIV

          -  Active infection for hepatitis B or C

          -  Decompensated cardiac failure

          -  Uncontrolled epilepsia

          -  Previous history of allogenic bone marrow transplantation

          -  Participation in other interventional drug research

          -  Patient deprived of liberty by a judicial or administrative decision or under the
             protection of justice

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the research protocol and follow-up schedule

          -  Patient under tutorship or curatorship

          -  Patient under psychiatric care according to art. L1121-6 CSP




18 Years - 75 Years

Accepts Healthy Volunteers



Saskia Oro, MD, 0149812536, [email protected]

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Assistance Publique - Hôpitaux de Paris

Study Sponsor

Saskia Oro, MD, Principal Investigator, [email protected]

Verification Date

April 2022